Apimeds Pharmaceuticals US, Inc

APUSAMEXHealthcare● Active

$1.28

+$0.01(+0.79%)

Market Cap$1609725

P/E Ratio—

52W High$40.31

52W Low$1.17

Avg Volume130K

Open$1.17

Beta-1.03

Earnings Financials Revenue

Apimeds Pharmaceuticals US, Inc (APUS) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

APUS · earnings · updated Jun 9, 2026

Latest Earnings

Q2 FY2026Report Date: May 26, 2026

EPS Actual

-$2.26

Revenue

—

Fiscal Period

Q2 FY2026

FY ends December

Report Date

May 26, 2026

After Market Close

APUS reports quarterly as a AMEX-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

$3.83

Days Away84

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.$3.83

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
— Q2 FY2026	May 26, 2026	—	-$2.26	—	—	—	—
— Q4 FY2025	Nov 12, 2025	—	-$0.14	—	—	—	—
— Q3 FY2025	Aug 19, 2025	—	-$0.26	—	—	—	—
— Q2 FY2025	May 19, 2025	—	-$0.05	—	—	—	—
— Q4 FY2024	Dec 31, 2024	—	-$0.02	—	—	—	—
— Q3 FY2024	Sep 30, 2024	—	-$0.03	—	—	—	—
— Q2 FY2024	Jun 30, 2024	—	-$0.04	—	—	—	—
— Q1 FY2024	Mar 31, 2024	—	-$0.02	—	—	—	—

Q2 FY2026

May 26, 2026

EPS Actual

-$2.26

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2025

Nov 12, 2025

EPS Actual

-$0.14

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2025

Aug 19, 2025

EPS Actual

-$0.26

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2025

May 19, 2025

EPS Actual

-$0.05

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2024

Dec 31, 2024

EPS Actual

-$0.02

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2024

Sep 30, 2024

EPS Actual

-$0.03

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2024

Jun 30, 2024

EPS Actual

-$0.04

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2024

Mar 31, 2024

EPS Actual

-$0.02

EPS Est.

—

EPS Surpr.

—

Revenue

—

No analyst estimates available for APUS.

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
— Q2 FY2026	May 26, 2026	—	$1.50	$1.42	-5.33%
— Q4 FY2025	Nov 12, 2025	—	$2.67	$2.68	+0.37%
— Q3 FY2025	Aug 19, 2025	—	$1.75	$1.90	+8.57%
— Q2 FY2025	May 19, 2025	—	$1.70	$1.79	+5.29%
— Q4 FY2024	Dec 31, 2024	—	No price data	$2.20	—
— Q3 FY2024	Sep 30, 2024	—	No price data	$2.20	—
— Q2 FY2024	Jun 30, 2024	—	No price data	$2.20	—
— Q1 FY2024	Mar 31, 2024	—	No price data	$2.20	—

Q2 FY2026-5.33%

Report Date

May 26, 2026

EPS Beat/Miss

—

Price Before

$1.50

Price After

$1.42

Q4 FY2025+0.37%

Report Date

Nov 12, 2025

EPS Beat/Miss

—

Price Before

$2.67

Price After

$2.68

Q3 FY2025+8.57%

Report Date

Aug 19, 2025

EPS Beat/Miss

—

Price Before

$1.75

Price After

$1.90

Q2 FY2025+5.29%

Report Date

May 19, 2025

EPS Beat/Miss

—

Price Before

$1.70

Price After

$1.79

Q4 FY2024—

Report Date

Dec 31, 2024

EPS Beat/Miss

—

Price Before

—

Price After

$2.20

Q3 FY2024—

Report Date

Sep 30, 2024

EPS Beat/Miss

—

Price Before

—

Price After

$2.20

Q2 FY2024—

Report Date

Jun 30, 2024

EPS Beat/Miss

—

Price Before

—

Price After

$2.20

Q1 FY2024—

Report Date

Mar 31, 2024

EPS Beat/Miss

—

Price Before

—

Price After

$2.20

Beat Rate0 / 8 quarters

Largest Move+8.57% (Q3 FY2025)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Apimeds Pharmaceuticals US, Inc (APUS) most recently reported earnings on May 26, 2026 for Q2 FY2026, posting EPS of $-2.26 (in line with the analyst consensus of —). The next APUS earnings date is expected around September 1, 2026.

Each quarter, investors track APUS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. APUS revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

APUS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

APUS earnings · 4 questions

Apimeds Pharmaceuticals US, Inc's next earnings report is expected around September 1, 2026. APUS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; APUS historically reports after market close (AMC).

APUS earnings datewhen is APUS earningsAPUS next earnings datewhen does APUS report earningsAPUS earnings calendar

▸ Source: FMP · Apimeds Pharmaceuticals US, Inc SEC filings · US GAAP · Apimeds Pharmaceuticals US, Inc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026